BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 12732671)

  • 1. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
    Gabriel M; Decristoforo C; Donnemiller E; Ulmer H; Watfah Rychlinski C; Mather SJ; Moncayo R
    J Nucl Med; 2003 May; 44(5):708-16. PubMed ID: 12732671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
    Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma.
    Kosowicz J; Mikołajczak R; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J
    Cancer Biother Radiopharm; 2007 Oct; 22(5):613-28. PubMed ID: 17979564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives.
    Decristoforo C; Mather SJ; Cholewinski W; Donnemiller E; Riccabona G; Moncayo R
    Eur J Nucl Med; 2000 Sep; 27(9):1318-25. PubMed ID: 11007513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs.
    Cwikla JB; Mikolajczak R; Pawlak D; Buscombe JR; Nasierowska-Guttmejer A; Bator A; Maecke HR; Walecki J
    J Nucl Med; 2008 Jul; 49(7):1060-5. PubMed ID: 18552141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of 99mTc-depreotide and 99mTc-EDDA/HYNIC-TOC thorax scintigrams acquired for the purpose of differential diagnosis of solitary pulmonary nodules.
    Płachcińska A; Mikołajczak R; Kozak J; Rzeszutek K; Kuśmierek J
    Nucl Med Rev Cent East Eur; 2006; 9(1):24-9. PubMed ID: 16791800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors.
    Trogrlic M; Tezak S
    Nucl Med Rev Cent East Eur; 2016; 19(2):74-80. PubMed ID: 27479884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma.
    Czepczyński R; Parisella MG; Kosowicz J; Mikołajczak R; Ziemnicka K; Gryczyńska M; Sowiński J; Signore A
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1635-45. PubMed ID: 17530247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical indications to the use of (99m)Tc-EDDA/HYNIC-TOC to detect somatostatin receptor-positive neuroendocrine tumors.
    Parisella MG; Chianelli M; D'Alessandria C; Todino V; Mikolajczak R; Papini E; Dierckx RA; Scopinaro F; Signore A
    Q J Nucl Med Mol Imaging; 2012 Feb; 56(1):90-8. PubMed ID: 21068709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
    Grimes J; Celler A; Birkenfeld B; Shcherbinin S; Listewnik MH; Piwowarska-Bilska H; Mikolajczak R; Zorga P
    J Nucl Med; 2011 Sep; 52(9):1474-81. PubMed ID: 21795364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.
    Gabriel M; Decristoforo C; Kendler D; Dobrozemsky G; Heute D; Uprimny C; Kovacs P; Von Guggenberg E; Bale R; Virgolini IJ
    J Nucl Med; 2007 Apr; 48(4):508-18. PubMed ID: 17401086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D; Mikołajczak R; Kamiński G
    Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved kit formulation for preparation of (99m)Tc-HYNIC-TOC: results of preliminary clinical evaluation in imaging patients with neuroendocrine tumors.
    Korde A; Mallia M; Shinto A; Sarma HD; Samuel G; Banerjee S
    Cancer Biother Radiopharm; 2014 Nov; 29(9):387-94. PubMed ID: 25379612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide.
    Meisetschläger G; Poethko T; Stahl A; Wolf I; Scheidhauer K; Schottelius M; Herz M; Wester HJ; Schwaiger M
    J Nucl Med; 2006 Apr; 47(4):566-73. PubMed ID: 16595488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
    Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
    Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of scintigraphy with the use of 99mTc-HYNIC-TOC in the diagnosis of medullary thyroid carcinoma].
    Czepczyński R; Kosowicz J; Ziemnicka K; Mikołajczak R; Gryczyńska M; Sowiński J
    Endokrynol Pol; 2006; 57(4):431-5. PubMed ID: 17006849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability.
    Haldemann AR; Rösler H; Barth A; Waser B; Geiger L; Godoy N; Markwalder RV; Seiler RW; Sulzer M; Reubi JC
    J Nucl Med; 1995 Mar; 36(3):403-10. PubMed ID: 7884502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide.
    Decristoforo C; Melendez-Alafort L; Sosabowski JK; Mather SJ
    J Nucl Med; 2000 Jun; 41(6):1114-9. PubMed ID: 10855644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT.
    Virgolini I; Angelberger P; Li S; Yang Q; Kurtaran A; Raderer M; Neuhold N; Kaserer K; Leimer M; Peck-Radosavljevic M; Scheithauer W; Niederle B; Eichler HG; Valent P
    Eur J Nucl Med; 1996 Oct; 23(10):1388-99. PubMed ID: 8781146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.